Radius Health Inc (OQ:RDUS)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 950 Winter St
WALTHAM MA 02451-1424
Tel: 1-617-4441979
Website: https://www.radiuspharm.com
IR: See website
Key People
Owen P. Hughes
Independent Chairman of the board
G. Kelly Martin
President, Chief Executive Officer, Director
Dan Dolan
Principal Financial Officer, Principal Accounting Officer, Treasurer
Chhaya Shah
Senior Vice President - Technical Operations
Charles Q. Morris
Chief Medical Officer
Business Overview
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Its clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis, and the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group. Elacestrant is a selective estrogen receptor degrader (SERD) being developed as a once daily oral treatment in patients with advanced estrogen receptor positive, HER2 negative, breast cancer.
Financial Overview
For the six months ended 30 June 2020, Radius Health Inc revenues increased 38% to $98M. Net loss increased 4% to $81.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 66% to $83.9M (expense), Interest expense increase of 12% to $13.7M (expense), Interest income decrease of 50% to $1.1M (income).
Employees: 383 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $713.11M as of Jun 30, 2020
Annual revenue (TTM): $200.47M as of Jun 30, 2020
EBITDA (TTM): -$110.95M as of Jun 30, 2020
Net annual income (TTM): -$136.29M as of Jun 30, 2020
Free cash flow (TTM): -$74.77M as of Jun 30, 2020
Net Debt Last Fiscal Year: $88.52M as of Jun 30, 2020
Shares outstanding: 46,472,327 as of Aug 3, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.